Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $603.61 million
- Book Value:
- Revenue TTM:
- $133.62 million
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Alector Inc had its IPO on 2019-02-07 under the ticker symbol ALEC.
The company operates in the Healthcare sector and Biotechnology industry. Alector Inc has a staff strength of 273 employees.
Shares of Alector Inc opened at $6.29 at the start of the last trading session i.e. 2023-03-28.
The stocks traded within a range of $6.16 - $6.39, and closed at $6.23.
This is a -1.27% slip from the previous day's closing price.
A total volume of 257,882 shares were traded at the close of the day’s session.
In the last one week, shares of Alector Inc have slipped by -2.5%.
Alector Inc's Key Ratios
Alector Inc has a market cap of $603.61 million, indicating a price to book ratio of 3.0649 and a price to sales ratio of 5.4898.
In the last 12-months Alector Inc’s revenue was $133.62 million with a gross profit of $-76801000 and an EBITDA of $-132120000. The EBITDA ratio measures Alector Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Alector Inc’s operating margin was -103.16% while its return on assets stood at -10.75% with a return of equity of -51.75%.
In Q4, Alector Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 3.2%.
Alector Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-1.61 per share while it has a forward price to earnings multiple of 526.3158 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Alector Inc’s profitability.
Alector Inc stock is trading at a EV to sales ratio of 0.4647 and a EV to EBITDA ratio of -0.4774. Its price to sales ratio in the trailing 12-months stood at 5.4898.
Alector Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $787.65 million
- Total Liabilities
- $93.81 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Alector Inc ended 2023 with $787.65 million in total assets and $0 in total liabilities. Its intangible assets were valued at $787.65 million while shareholder equity stood at $214.44 million.
Alector Inc ended 2023 with $0 in deferred long-term liabilities, $93.81 million in other current liabilities, in common stock, $-579687000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $154.32 million and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.
Alector Inc’s total current assets stands at $726.44 million while long-term investments were $0 and short-term investments were $558.53 million. Its net receivables were $0 compared to accounts payable of $4.19 million and inventory worth $0.
In 2023, Alector Inc's operating cash flow was $0 while its capital expenditure stood at $766000.
Comparatively, Alector Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Alector Inc stock is currently trading at $6.23 per share. It touched a 52-week high of $15.72 and a 52-week low of $15.72. Analysts tracking the stock have a 12-month average target price of $20.
Its 50-day moving average was $8.16 and 200-day moving average was $9.29 The short ratio stood at 9.13 indicating a short percent outstanding of 0%.
Around 1100.3% of the company’s stock are held by insiders while 8160.6% are held by institutions.
Frequently Asked Questions About Alector Inc
Similar Industry Stocks (Biotechnology)
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer’s disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer’s disease. Its pipeline products include AL044 that targets MS4A4A, a risk gene for Alzheimer’s disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001, AL002, and AL101 to treat neurodegenerative diseases. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.